Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- FRONTIERIndependent statistical analysis of Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- FRONTIER 1Independent statistical analysis of A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05223868).
- FRONTIER-IIndependent statistical analysis of Safety and Performance Study of Large Hole Vascular Closure Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01943344).
- FROZEN-AFIndependent statistical analysis of Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- FSHDIndependent statistical analysis of Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir: Complete Statistical AnalysisIndependent statistical analysis of FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- FuchsIndependent statistical analysis of A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy: primary endpoint results, effect estimate…
- Fucidin® Cream in the Treatment of Impetigo: Complete Statistical AnalysisIndependent statistical analysis of Fucidin® Cream in the Treatment of Impetigo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00986856).
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole: Complete Statistical AnalysisIndependent statistical analysis of Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00543127).
- Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00617188).
- Functional ComprEhensive AssessmenT by IVUS Reconstruction in Patients With Suspected IschEmic Heart Disease (FEATURE): Complete Statistical AnalysisIndependent statistical analysis of Functional ComprEhensive AssessmenT by IVUS Reconstruction in Patients With Suspected IschEmic Heart Disease (FEATURE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke: Complete Statistical AnalysisIndependent statistical analysis of Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142792).
- Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke: Complete Statistical AnalysisIndependent statistical analysis of Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02199795).
- Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia: Complete Statistical AnalysisIndependent statistical analysis of Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00507546).
- Functionally-tailored Oral Care Intervention for Community-dwelling Older Adults With Dementia and Their Caregivers: Complete Statistical AnalysisIndependent statistical analysis of Functionally-tailored Oral Care Intervention for Community-dwelling Older Adults With Dementia and Their Caregivers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): Complete Statistical AnalysisIndependent statistical analysis of Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Fusion Targeted Biopsy of the Prostate: Complete Statistical AnalysisIndependent statistical analysis of Fusion Targeted Biopsy of the Prostate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02013414).
- FUTR-30Independent statistical analysis of Discharge Follow-up Phone Call Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03050918).
- FUTUREIndependent statistical analysis of Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- FUTURE 2Independent statistical analysis of Bosentan in Children With Pulmonary Arterial Hypertension Extension Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00319020).
- FX-322 in Sensorineural Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of FX-322 in Sensorineural Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03616223).
- G-BMTIndependent statistical analysis of Buprenorphine Group Medical Visits in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02526212).
- G-Pen™ for Hypoglycemia Rescue in T1D Patients: Complete Statistical AnalysisIndependent statistical analysis of G-Pen™ for Hypoglycemia Rescue in T1D Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02423980).
- GA YAZ ACNE in China Phase III: Complete Statistical AnalysisIndependent statistical analysis of GA YAZ ACNE in China Phase III: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00818519).
- Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gabapentin for Postop Pain After SSLF: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Postop Pain After SSLF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03123861).
- Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00880191).
- Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01143766).
- Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00420771).
- GABLEIndependent statistical analysis of Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03515941).
- GADIndependent statistical analysis of Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GadaCAD 1Independent statistical analysis of Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GADinLADAIndependent statistical analysis of Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GAINIndependent statistical analysis of Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GalaNicIndependent statistical analysis of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02420327).
- Galcanezumab for Vestibular Migraine: Complete Statistical AnalysisIndependent statistical analysis of Galcanezumab for Vestibular Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04417361).
- GALILEO-4DIndependent statistical analysis of Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed…
- Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence: Complete Statistical AnalysisIndependent statistical analysis of Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAMINIIIndependent statistical analysis of Gut and Azithromycin Mechanisms in Infants and Children II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04315272).
- Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01232829).
- Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study: Complete Statistical AnalysisIndependent statistical analysis of Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00129441).
- GammozIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ganaxolone Treatment in Children With Fragile X Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Ganaxolone Treatment in Children With Fragile X Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01725152).
- GANDRIndependent statistical analysis of Revolutionizing Normative Re-education: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04356261).
- GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy: Complete Statistical AnalysisIndependent statistical analysis of GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02012192).
- Gao Bipolar Spectrum Lithium/Quetiapine Study: Complete Statistical AnalysisIndependent statistical analysis of Gao Bipolar Spectrum Lithium/Quetiapine Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01526148).
- Gao NARASD Lithium Study: Complete Statistical AnalysisIndependent statistical analysis of Gao NARASD Lithium Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02909504).
- Gardasil Vaccination in Post Stem Cell Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Gardasil Vaccination in Post Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01092195).